Ehlers-Danlos syndrome, with special emphasis in the joint hypermobility syndrome;Síndrome de Ehlers-Danlos con especial énfasis en el síndrome de hiperlaxitud articular

Revista Medica de Chile

Volumn 137, Issue 11, 2009, Pages 1488-1497

  Bravo, Jaime F ^a  

^a HOSPITAL SAN JUAN DE DIOS   (Chile)

Author keywords

Ehlers Danlos syndrome; Fibromyalgia; Joint instability

Indexed keywords

ADOLESCENT; ADULT; DIFFERENTIAL DIAGNOSIS; EHLERS DANLOS SYNDROME; FACIES; HUMAN; JOINT INSTABILITY; REVIEW; SYNDROME; EHLERS-DANLOS SYNDROME; YOUNG ADULT;

ADOLESCENT; DIAGNOSIS, DIFFERENTIAL; EHLERS-DANLOS SYNDROME; FACIES; HUMANS; JOINT INSTABILITY; SYNDROME; YOUNG ADULT;

EID: 72249112028     PISSN: 00349887     EISSN: 07176163     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. Mishra MB, Ryan P, Atkinson P, Taylor H, Bell J, Calver D et al. Extra-articular features of benign joint hypermobility syndrome. Br J Rheumtol 1996; 35: 861-6.
2. Grahame R. Joint hypermobility and genetic collagen disorders: are they related? Arch Dis Child 1999; 80: 188-91.
3. Larsson LG, Baum J, Mudholkar GS, Srivastava DK. Hypermobility prevalence and features in Swedish population. Br J Rheumatol 1993; 32: 116-9.
4. Beighton PH, Solomon L, Soskolne CL. Articular mobility in an African population. Ann Rheum Dis 1973; 32: 413-8.
5. Grahame R, Bird HA, Child A, Dolan L, Edwards-Fowler A, Ferrell WR et al. The revised (Brighton 1998) criteria for the diagnosis of the benign joint hypermobility syndrome. J Rheumatol 2000; 27: 1777-9.
6. Beighton P, Depaepe A, Steinmann B, Tsipouras P, Wenstrup RJ. Ehlers-Danlos syndromes: revised no-sology, Villefranche, 1977. Am J Med Gen 1998; 77: 31-7.
7. Pope FM, Martin GR, Lichtenstein JR, Penttinen R, Gerson B, Rowe DW, Mckusic VA. Patients with Ehlers-Danlos type IV lack type III collagen. Proc Nat Acad Sci USA 1975; 72: 1314-6.
8. Bravo JF. Precauciones y posibles complicaciones quirúrgicas de las alteraciones hereditarias de la fibra colágena (AHFC). Rev Chil Cirugía 2005; 57: 516-22.
9. Bravo JF. Síndrome de Ehlers-Danlos vascular (SEDV), antes llamado SED tipo IV. Rev Chil Reuma-tol 2008; 24: 6-11.
10. Pepin M, Schwarze U, Superti-Furga A, Byers PH. Clinical and genetic features of Ehlers-Danlos syndrome type IV, the vascular type. N Engl J Med 2000; 342: 673-80.
11. Guma M, Olivé A, Holgado S, Casado E, Roca J, Forcada J et al. Una estimación de la laxitud articular en la consulta externa. Rev Esp Reumatol 2001; 28: 298-300.
12. Grahame R, Hakim AJ. Joint hypermobility syndrome is highly prevalent in general rheumatology clinics, presentation being gender, age and race-related. Ann Rheum Dis 2006; 65 (Suppl 2): 263.
13. Grahame R, Hakim AJ. Hypermobility. Curr Opin Rheumatol 2008; 20: 106-10.
14. Bravo JF, Wolff C, Correa S. Clinical study of 972 rheumatological patients with joint hypermobility syndrome (JHS), using the Brighton criteria. Ann Rheum Dis 2007; 66 (Suppl II): 244 (Abstract).
15. Bravo JF, Wolff C. Clinical study of hereditary disorders of connective tissues in a Chilean population. Joint hypermobility syndrome and vascular Ehlers-Danlos syndrome. Arthritis Rheum 2006; 54: 515-23.
16. Grahame R. Editorial: Time to take hypermobility seriously (in adults and children). Rheumatology 2001; 40: 485-91.
17. Grahame R, Bird HA. British consultant rheumatologists perceptions about the hypermobility syndrome: a national survey. Rheumatology 2001; 40: 560-3.
18. Child AH. Joint Hypermobility Syndrome: inherited disorder of collagen synthesis. J Rheumatol 1986; 13: 239-42.
19. Hermanns-Le T, Pierard GE. Ultra structural alterations of elastic fibers and other dermal components in Ehlers-Danlos syndrome of the hypermobile type. Am J Dermatopathol 2007; 29: 370-3.
20. Zweers MC, Hakim AJ, Grahame R, Schalkwijk J. Joint hypermobility syndromes: the pathophysiologic role of Tenascin-X gene defects [review]. Arthritis Rheum 2004; 50: 2742-9.
21. Levy HP. Ehlers-Danlos Syndrome, Hypermobility Type. http://genetests.org/profiles/eds3/ 22 Oct. 2004.
22. Bravo JF, Wolff C. Clinical study of 1124 cases of Ehlers-Danlos syndrome (Classic EDS, JHS and Vascular EDS). Arthritis Rheum 2007; 56 (Suppl): 1633. (Abstract).
23. Bird HA, Tribe CR, Bacon PA. Joint hypermobility leading to osteoarthritis and condrocalcinosis. Ann Rheum Dis 1978; 37: 203-11.
24. Rojas C, Aris H, Carvallo A. Esclerosis sistémica progresiva. Análisis clínico de 90 casos. Libro de resúmenes XV Congreso Chileno de Reumatologi ́a 1982; pp. 3.
25. Saraux A, Allain J, Guedes C, Baron D, Youinou P, Le Goff P. Raynaud's phenomenon in rheumatoid. Arthritis 1996; 35: 752-4.
26. Maricq HR, Carpentier PH, Weinrich MC, Keil JE, Franco A, Drouet P. et al Geographic variation in the presence of Raynaud's phenomenon. Charleston, SC, USA vs. Tarentaise, Savoie, France. J Rheumatol 1993; 20: 70-6.
27. Bravo JF, Wolff C. Clinical study of Dysautonomia in 1226 patients with Joint Hypermobility Syndrome. J Clin Rheumatol 2008; 14 (Suppl): S33 (Abstract).
28. Rowe PC, Barron DF, Calkins H, Maumenee T, Tong PY, Geraghty MT. Orthostatic intolerance and chronic fatigue syndrome associated with Ehlers-Danlos syndrome. J Pediatr 1999; 135: 494-9.
29. Gazit Y, Nahir AM, Grahame R, Jacob G. Dysautonomia in the joint hypermobility syndrome. Am J Med 2003; 115: 33-40.
30. Arendt-Nielsen L, Kaalund P, Bjerring P, Hogsaa B. Insufficient effect of local analgesics in Ehlers-Danlos type III patients (connective tissue disorder). Acta Anaesthesiol Scand 1990; 34: 358-61.
31. Mallik AK, Ferrel WR, Mcdonald AG, Sturrock RD. Impaired propioceptive acuity at the proximal interphalangeal joint in patients with the hypermobility syndrome. Br J Rheum 1994; 33: 631-7.
32. Gratacos M, Nadal M, Martin-Santos R, Pujana MA, Gago J, Peral B et al. A polymorphic genomic duplication on human chromosome 15 is a susceptibility factor for panic and phobic disorders. Cell 2001; 106: 367-9.
33. Dolan AL, Arden NK, Grahame R, Spector TD. Assessment of bone in Ehlers-Danlos syndrome by ultrasound and densitometry. Ann Rheum Dis 1998; 57: 630-3.
34. De Paepe A, Devereux RB, Dietz HC, Hennekam RC, Pyeritz RE. Revised diagnostic criteria for the Marfan syndrome. Am J Med Gen 1996; 62: 417-26.
35. Bravo JF. Importancia de la hipermovilidad articular como causa frecuente de morbilidad, no sólo músculo-esquelética, sino también sistémica: criterios diagnósticos. Reumatología 2003; 19: 33-8.
36. Gedalia A, Press J, Klein M, Buskila D. Joint hypermobility and fibromyalgia in school children. Ann Rheum Dis 1993; 52: 494-6.
37. Barron DF, Cohen BA, Geraghty MT, Violand R, Rowe PC. Joint hypermobility is more common in children with chronic fatigue syndrome than in healthy controls. J Pediatr 2002; 141: 421-5.
38. Acasuso-Díaz M, Collantes-Estevez E. Joint hypermobility in patients with fibromyalgia syndrome. Arthri-tis Care & Research 1998; 11: 39-42.
39. Engelbert RHH, Bank RA, Sakkers RJB, Helders PJM, Beemer FA, Uiterwaal CSP et al. Pediatric generalized joint hypermobility with and without musculoskeletal complaints: localized or systemic disorder? Pediatr 2003; 111: 248-54.
40. Keer R, Grahame R. Hypermobility Syndrome. Recognition and management for physiotherapists. Edited by Butterworth Heinemann. London. UK. Imprint by Elsevier Science Limited, 2003.
41. Mclean RR, Jacques PF, Selhub J, Tucker KL, Samelson EJ, BROE KE et al. Homocysteine as a predictive factor for hip fracture in older persons. N Engl J Med 2004; 350: 2042-9.
42. Reginster JY, Deroisy R, Rovati LC, Lee RL, Lejeune E, Bruyere O et al. Long term effects of glucosamine sulphate in the progression of osteoarthritis: aleatory clinical study, controlled with placebo. Lancet 2001; 357: 251-6.
43. Leeb BF, Schweitzer H, Montag K, Smolen JS. A metaanalysis of chondroitin sulfate in the treatment of osteoarthritis. J Rheumatol 2000; 27: 205-11.